F 0002
Alternative Names: F-0002; F0002-ADCLatest Information Update: 03 Feb 2025
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies
Most Recent Events
- 07 Dec 2024 Adverse events and efficacy data from a phase I trial in Haematological malignancies presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 24 May 2024 Phase I development is ongoing in China (Parenteral) (NCT03894150)
- 12 Mar 2024 Shanghai Fudan-Zhangjiang Bio completes a phase I trial in Haematological malignancies (Second-line therapy or greater) in China (Parenteral) (NCT03894150)